Title |
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
|
---|---|
Published in |
Cancer Immunology, Immunotherapy, May 2015
|
DOI | 10.1007/s00262-015-1707-3 |
Pubmed ID | |
Authors |
Peter F. Mulders, Maria De Santis, Thomas Powles, Karim Fizazi |
Abstract |
Prostate cancer remains highly prevalent and has a poor clinical outcome once metastatic. Sipuleucel-T is an autologous cellular immunotherapy approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T treatment extends survival but is independent of traditional short-term markers of treatment response observed with chemotherapy and contemporary hormonal treatments. Therefore, it is essential that clinicians understand the mechanism of action of sipuleucel-T and how this can translate in the clinic. This article aims to summarize the current knowledge of sipuleucel-T therapy and its effects in mCRPC. Relevant publications describing sipuleucel-T clinical data and information relating to immunotherapies were identified. Treatment with sipuleucel-T extends survival, with side effects being usually mild or moderate and manageable within the outpatient setting. The long-term immune responses generated by sipuleucel-T correlate with a survival benefit. Sipuleucel-T shows a greater magnitude of clinical benefit when used in patients earlier in the mCRPC setting. Sipuleucel-T stimulates long-lived immune responses that translate into long-term clinical benefit. The treatment course (three infusions at weeks 0, 2, and 4) is associated with manageable side effects. Short-term markers of future benefit would be clinically useful, and information on effective treatment combinations or sequences is awaited. Sipuleucel-T treatment directs the patient's own immune system to target and remove prostate cancer cells and increases life expectancy. Patients whose cancer is less advanced generally have a more 'active' immune system and may benefit the most from this treatment. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 66 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 12 | 18% |
Student > Ph. D. Student | 10 | 15% |
Student > Master | 7 | 11% |
Researcher | 6 | 9% |
Student > Doctoral Student | 5 | 8% |
Other | 12 | 18% |
Unknown | 14 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 21 | 32% |
Biochemistry, Genetics and Molecular Biology | 9 | 14% |
Agricultural and Biological Sciences | 7 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
Chemistry | 3 | 5% |
Other | 7 | 11% |
Unknown | 15 | 23% |